Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA sinks Gaviscon "floating" claim

Executive Summary

Marion's petition to amend the final monograph for OTC antacid drug products to include the ingredient alginic acid and the labeling claim "floating" denied by FDA. Agency said its advisory review panel recognized that alginic acid-containing products may produce a layer of material floating on top of the contents of the stomach but concluded that there was insufficient evidence to support the claim that such a property contributes to the product's effectiveness. Gaviscon, which was approved via NDA, includes alginic acid as an inactive ingredient.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012441

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel